000 02252cam  2200445zi 4500
0019.884429
003CaOODSP
00520221107170850
006m     o  d f      
007cr cn|||||||||
008200207t20202020onc     ob   f000 0 eng d
020 |a9780660339962
020 |z9780660339979|q(incorrect)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH14-311/2020E-PDF
24500|aGuidance on drug establishment licences.
24617|aGuidance on drug establishment licences, version 8 (GUI-0002)
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2020.
264 4|c©2020
300 |a1 online resource (45 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Document d'orientation sur les licences d'établissement de produits pharmaceutiques.
500 |a"GUI-0002."
500 |a"April 1, 2020."
500 |a"Pub.: 190596."
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references (pages 42-45).
520 |a"This guide is for companies in the drug manufacturing industry. It will help to facilitate understanding and compliance with Part C, Division 1A of the Food and Drug Regulations (FDR with regards to drug establishment licence (DEL) requirements"--Purpose, page 6.
650 0|aPharmaceutical industry|xLicenses|zCanada.
650 0|aPharmaceutical industry|xSafety regulations|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tDocument d'orientation sur les licences d'établissement de produits pharmaceutiques.|w(CaOODSP)9.884432
795 |tGuidance on drug establishment licences and associated fees.|w(CaOODSP)9.869653
85640|qPDF|s1.51 MB|uhttps://publications.gc.ca/collections/collection_2020/sc-hc/H14-311-2020-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-drug-establishment-licences-drug-establishment-licensing-fees-0002/document.html